RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Bionano Genomics Stock

Bionano Genomics Employees 2024

Bionano Genomics Employees

147

Ticker

BNGO

ISIN

US09075F1075

WKN

A2JRLZ

In 2024, Bionano Genomics employed 147 people, a 0% change from the 147 number of employees in the previous year.

Bionano Genomics Aktienanalyse

What does Bionano Genomics do?

Bionano Genomics Inc. is a biotechnology company specializing in the development of DNA analysis systems. The company is headquartered in California and was founded in 2003. History: The company was originally established as a research group at the University of California, San Diego. Over the years, the group has evolved into a leading company in DNA analysis and genome analysis. Business model: Bionano Genomics Inc. has a business model based on the analysis and processing of DNA sequences. The company offers its products and services in three different business areas: genomic research, clinical research, and diagnostics. Products: The company has introduced a range of products that help revolutionize genomics. One of Bionano Genomics' most important products is the Saphyr system. This system uses optical DNA mapping technology to make DNA sorting and mapping more efficient. The Saphyr system can contribute to improving and accelerating genomic research in various industries. Another product of the company is the COVID-19 assay. This assay is used in the detection of COVID-19. It is used in the laboratory and is fast and accurate. Divisions: Bionano Genomics offers its products and services in three different business areas: genomic research, clinical research, and diagnostics. Genomic research: Bionano Genomics works closely with research institutes and companies to perform DNA analysis. The Saphyr system is used to analyze DNA samples and conduct genome studies. With this technology, it has become possible to visualize large genomic regions to gain insights into complex genomic changes and rearrangements, such as those related to cancer. Clinical research: The company works closely with clinicians to conduct clinical studies and diagnose diseases. The Saphyr system can help in the investigation of structural DNA variants associated with specific diseases such as autism, schizophrenia, and epilepsy. Diagnostics: Bionano Genomics also offers services for the diagnosis of genetic disorders. The company provides tests that examine genetic markers and indicators to make an accurate diagnosis. The company also offers genetic counseling services to help families affected by genetic diseases. Overall, Bionano Genomics has the potential to change the way we study, diagnose, and treat genetic diseases. The company has already formed partnerships with several industry leaders and research institutions to advance its research. Bionano Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Bionano Genomics's Employee Base

Bionano Genomics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Bionano Genomics's operational capacity and future potential.

Year-to-Year Comparison

Assessing Bionano Genomics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Bionano Genomics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Bionano Genomics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Bionano Genomics stock

How many employees does Bionano Genomics have this year?

Bionano Genomics has 147 undefined employees this year.

How many employees did Bionano Genomics have compared to the previous year?

Compared to the previous year, Bionano Genomics had 0% more employees.

What impact did the number of employees have on the company Bionano Genomics?

The number of employees has a direct impact on the efficiency and productivity of Bionano Genomics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Bionano Genomics?

The number of employees can also have an impact on investors of Bionano Genomics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Bionano Genomics affect the company?

An increase in equity of Bionano Genomics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Bionano Genomics's equity affect the company?

A reduction in equity of Bionano Genomics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Bionano Genomics?

Some factors that can influence the equity of Bionano Genomics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Bionano Genomics so important for investors?

The equity of Bionano Genomics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Bionano Genomics influence the company?

The number of employees at Bionano Genomics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Bionano Genomics evolved in recent years?

In recent years, the number of employees at Bionano Genomics has changed by 0.

How many employees does Bionano Genomics currently have?

Bionano Genomics currently has 147 undefined employees.

Why is the number of employees important for investors of Bionano Genomics?

The number of employees is important for investors of Bionano Genomics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Bionano Genomics take to change the number of employees?

To change the number of employees, Bionano Genomics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Bionano Genomics pay?

Over the past 12 months, Bionano Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bionano Genomics is expected to pay a dividend of 0 USD.

What is the dividend yield of Bionano Genomics?

The current dividend yield of Bionano Genomics is .

When does Bionano Genomics pay dividends?

Bionano Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bionano Genomics?

Bionano Genomics paid dividends every year for the past 0 years.

What is the dividend of Bionano Genomics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bionano Genomics located?

Bionano Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bionano Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bionano Genomics from 11/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/16/2024.

When did Bionano Genomics pay the last dividend?

The last dividend was paid out on 11/16/2024.

What was the dividend of Bionano Genomics in the year 2023?

In the year 2023, Bionano Genomics distributed 0 USD as dividends.

In which currency does Bionano Genomics pay out the dividend?

The dividends of Bionano Genomics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Bionano Genomics

Our stock analysis for Bionano Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bionano Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.